currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.

Takeda’s CEO Christophe Weber got the deal across the line despite protests from a small but vocal group of shareholders concerned about repaying the bank loan of more than $30 billion needed to ...

Takeda Pharmaceuticals has named Julie Kim as the first woman ... Kim, a US citizen and head of the firm's US business, will next year succeed Christophe Weber who in 2015 became the drugmaker's first ...

After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...